A contemporary look at thyroid nodule management

References

1. ↵
   1. Guth S,
   2. Theune U,
   3. Aberle J,
   4. Galach A,
   5. Bamberger CM

   (2009) Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 39:699–706.

   OpenUrlCrossRefPubMed
2. ↵
   1. Jiang H,
   2. Tian Y,
   3. Yan W,
   4. Kong Y,
   5. Wang H,
   6. et al.

   (2016) The prevalence of thyroid nodules and an analysis of related lifestyle factors in Beijing communities. Environ Res Public Health 13:442.

   OpenUrl
3. ↵
   1. Haugen BR,
   2. Alexander EK,
   3. Bible KC,
   4. Doherty GM,
   5. Mandel SJ,
   6. Nikiforov YE

   (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer, The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133.

   OpenUrlCrossRefPubMed
4. ↵
   1. Russ G,
   2. Bonnema SJ,
   3. Erdogan MF,
   4. Durante C,
   5. Ngu R,
   6. Leenhardt L

   (2017) European thyroid association guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults:the EU-TIRADS. Eur Thyroid J 6:225–237.

   OpenUrlCrossRefPubMed
5. ↵
   1. Cibas ES,
   2. Ali SZ

   (2017) The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid 27:1341–1346.

   OpenUrlCrossRefPubMed
6. ↵
   1. Alexander EK,
   2. Kennedy GC,
   3. Baloch ZW,
   4. Cibas ES,
   5. Chudova D,
   6. Diggans J,
   7. et al.

   (2012) Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367:705–715.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Nicholson K,
   2. Roberts MS,
   3. McCoy KL,
   4. Carty SE,
   5. Yip L

   (2019) Molecular Testing Versus Diagnostic Lobectomy in Bethesda III/IV Thyroid Nodules:A Cost-Effectiveness Analysis. Thyroid 29:1237–1243.

   OpenUrl
8. ↵
   1. Hahn SY,
   2. Shin JH,
   3. Na DG,
   4. Ha EJ,
   5. Ahn HS,
   6. Lim HK,
   7. et al.

   (2019) Ethanol ablation of the thyroid nodules:2018 consensus statement by the Korean society of thyroid radiology. Korean J Radiol 20:609–620.

   OpenUrl
9. ↵
   1. Suh CH,
   2. Baek JH,
   3. Ha EJ,
   4. Choi YJ,
   5. Lee JH,
   6. Kim JK,
   7. et al.

   (2015) Ethanol ablation of predominantly cystic thyroid nodules:Evaluation of recurrence rate and factors related to recurrence. Clinical Radiology 70:42–47.

   OpenUrl
10. ↵
    1. Kim JH,
    2. Baek JH,
    3. Lim HK,
    4. Ahn HS,
    5. Baek SM,
    6. Choi YJ,
    7. et al.

    (2018) 2017 Thyroid Radiofrequency Ablation Guideline:Korean Society of Thyroid Radiology. Korean J Radiol 19:632–655.

    OpenUrl
11. ↵
    1. Mauri G,
    2. Gennaro N,
    3. Lee MK,
    4. Baek JH

    (2019) Laser and radiofrequency ablations for benign and malignant thyroid tumors. Int J Hyperthermia 36:13–20.

    OpenUrl
12. ↵
    1. Davies L,
    2. Morris LG,
    3. Haymart M,
    4. Chen AY,
    5. Goldenberg D,
    6. Morris J,
    7. et al.

    (2015) American Association of Clinical Endocrinologists and American College of Endocrinology Disease State clinical review:the increasing incidence of thyroid cancer. Endocr Pract 21:686–696.

    OpenUrlCrossRefPubMed
13. ↵
    1. Morris LG,
    2. Sikora AG,
    3. Tosteson TD,
    4. Davies L

    (2013) The increasing incidence of thyroid cancer:the influence of access to care. Thyroid 23:885–891.

    OpenUrlCrossRefPubMed
14. ↵
    1. Park S,
    2. Oh CM,
    3. Cho H,
    4. Lee JY,
    5. Jung KW,
    6. Jun JK,
    7. et al.

    (2016) Association between screening and the thyroid cancer “epidemic”in South Korea:evidence from a nationwide study. BMJ 355:i5745.

    OpenUrlAbstract/FREE Full Text
15. ↵
    1. Liang TJ,
    2. Liu SI,
    3. Mok KT,
    4. Shi HY

    (2016) Associations of volume and thyroidectomy outcomes:a nationwide study with systematic review and meta-analysis. Otolaryngol Head Neck Surg 155:65–75.

    OpenUrlCrossRefPubMed
16. ↵
    1. Al-Qurayshi Z,
    2. Robins R,
    3. Hauch A,
    4. Randolph GW,
    5. Kandil E

    (2016) Association of surgeon volume with outcomes and cost savings following thyroidectomy:a national forecast. JAMA Otolaryngol Head Neck Surg 142:32–39.

    OpenUrl
17. ↵
    1. Bates MF,
    2. Lamas MR,
    3. Randle RW,
    4. Long KL,
    5. Pitt SC,
    6. Schneider DF,
    7. et al.

    (2018) Back so soon?Is early recurrence of papillary thyroid cancer really just persistent disease? Surgery 163:118–123.

    OpenUrl
18. ↵
    1. Miller JE,
    2. Al-Attar NC,
    3. Brown OH,
    4. Shaughness GG,
    5. Rosculet NP,
    6. Avram AM,
    7. et al.

    (2018) Location and causation of residual lymph node metastasis after surgical treatment of regionally advanced differentiated thyroid cancer. Thyroid 28:593–600.

    OpenUrl
19. ↵
    1. Tuttle RM,
    2. Haugen B,
    3. Perrier ND

    (2017) Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition):What changed and why? Thyroid 27:751–756.

    OpenUrlCrossRef
20. ↵
    1. National Cancer Institute

    SEER Cancer Statistics Review (CSR) 1975-2015, [Updated 2018. April 2018], Available from URL: https://seer.cancer.gov/csr/1975_2015/.
21. ↵
    1. Nikiforov YE,
    2. Seethala RR,
    3. Tallini G,
    4. Baloch ZW,
    5. Basolo F,
    6. Thompson LD,
    7. et al.

    (2016) Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma:a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol 2:1023–1029.

    OpenUrl
22. ↵
    1. Clement SC,
    2. Peeters RP,
    3. Ronckers CM,
    4. Links TP,
    5. van den Heuvel-Eibrink MM,
    6. Nieveen van Dijkum EJ,
    7. et al.

    (2015) Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma-a systematic review. Cancer Treat Rev 41:925–934.

    OpenUrlCrossRefPubMed